Form 8-K - Current report:
SEC Accession No. 0001714899-24-000168
Filing Date
2024-08-01
Accepted
2024-08-01 06:48:19
Documents
15
Period of Report
2024-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20240801.htm   iXBRL 8-K 30513
2 EX-99.1 ex991pressreleaseq22024.htm EX-99.1 103555
6 denali_txlogox02.jpg GRAPHIC 604226
  Complete submission text file 0001714899-24-000168.txt   1095995

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20240801.xsd EX-101.SCH 1934
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20240801_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20240801_pre.xml EX-101.PRE 12530
17 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20240801_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 241164101
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)